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It has also been proposed to avoid the adverse effects

DERIVATIVE 0F ASPIRIN

of Z-acetoxybenzoic acid by the use of various esteri?ed
derivatives thereof, wherein transient blocking of the
acidic carboxylic group'of aspirin occurs. For instance,
French Patent No.’ Ml453'de'scribes various antipyretic
and analgesic compounds formed by esterifying 2
acetoxybenzoic acid with various sugars. Whether such
derivatives are viable substitutes for Z-acetoxybenzoic
acid depends not only upon whether these derivatives

BACKGROUND OF THE-‘INVENTION
1. Field of the Invention

.

The present invention relates to 2-acetoxybenzoic
acid and more particularly, the present invention relates
to a therapeutically useful derivative of 2-acetoxyben

zoic acid, i.e., l-O-(2’—acetoxy)benzoyl-a-D-2-deoxy

have therapeutic value per se, but to a larger extent

_ glucopyranose.

upon whether these derivatives have the potential to
revert to 2-acetoxybenzoic acid by hydrolysis in vivo.
In this regard, it is notable that certain derivatives of
2-acetoxybenzoic acid tend to hydrolyze so as to form
the corresponding ester of salicylic acid and not aspirin.
The following reaction scheme serves to illustrate the
manner in which derivatives of 2-acetoxybenzoic acid

The novel compound of this invention exhibits anal

gesic, antipyretic, and 'antirheumatic therapeutic activ

ity.
The compound, 2-acetoxybenzoic acid, is commonly
known as “aspirin” and/or “acetylsalicylic acid”, and is
one of the most widely used compounds in the treat

ment of simple pain and in?ammation. 2-Acetoxyben
zoic acid is widely employed as an analgesic, an antipy
retic, an anti-inflammatory and an antirheumatic agent,
and it is particularly useful in the relief of fever, head

may hydrolyze:

ache, myalgia, arthralgia and other pains associated
with integumental structures. 2-Acetoxybenzoic acid is

‘

II

II

c-o-n

c-o-n

generally administered for these conditions in the form
of a powder, particle, capsule, solution, tablet or other
pharmaceutically acceptable dosage form because it is
advantageous from the standpoint that chronic use of
the compound will not lead to a tolerance of addiction

Z-Acetoxybenzoic Acid Ester

thereof. Moreover, its toxicity is much lower than most

Z-Acetoxybenzoic Acid

compounds possessing similar pharmacologic activity.
However, 2-acetoxybenzoic acid, as'used for these pur
poses, is well-known by the practicing skilled artisan of

\l/ (11)

the medical arts to exhibit certain unwanted and

deliterious side effects'?Speci?cally, it induces occult
hemorrhaging in the gastrointestinal tract, which ‘results
from contact of the insoluble solid particulate of the
compound with the gastrointestinal mucosa. As a result

of this insolubilization, the very acidic particles of 2
acetoxybenzoic acid will adhere to the gastrointestinal
mucosa in the form of crystals and such crystals, taken
together with the acidic environment of the gastrointes

Salicylic Acid Ester

tinal lining, will produce microetching thereof, which
in turn, leads to gastrointestinal bleeding.
2. Description of the Prior Art
.

'

To date, it is known that gastric bleeding can be
diminished if (1) an aqueous solution of 2-acetoxyben
zoic acid is administered, or (2) a buffered aqueous

solution of 2-acetoxybenzoic acid is administered. How
ever, such solutions leave much to be desired in that

they are commercially and consumerwise unacceptable,

It is apparent that only those esteri?ed derivatives of
45

Z-acetoxybenzoic acid which hydrolyze according to
reaction scheme (I), so as to produce aspirin, are viable

substitutes for aspirin. Also, such a substitute must hy
drolyze at a rate sufficient to release aspirin in therapeu

tically effective quantities.
It has recently been discovered that the aspirin deriv

i.e., water and/or buffered solutions are unacceptable as

ative,

a suitable pharmaceutical‘dosage form. _

tends to hydrolyze so as to form the corresponding

l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose,

sugar derivative of salicylic acid, as per reaction scheme
(II) depicted above. Furthermore, to the extent that
2-acetoxybenzoic‘acid formulation, which, does exhibit 55 hydrolysis to aspirin takes place, such hydrolysis takes _
place only at a very slow rate.
satisfactory water'solubility and dissolution, insofar as
In summary, the various prior art sugar derivatives of
2-acetoxybenzoic acid is concerned. However, at least
2-acetoxybenzoic acid present a non-irritating neutral
three disadvantages are associated with this product.
molecule to the gastrointestinal lining when adminis
Firstly, the product is contained in a tablet 'form and
must initially be dissolved in water prior to consump 60 tered for therapeutic purposes. However, the group
which blocks the carboxylic acid function of Z-acetox
tion. Secondly, because ‘the product contains a high
ybenzoic acid tends to be bound thereto very tightly.
amount of sodium ion, it is unacceptable for administra
Such prior art derivatives, therefore, do not release
tion to hypertensive patientstthose who suffer from
One product on the market, commercially known as

“Alka-Seltzer ®" is basically an alkaline effervescent

aspirin in vivo in therapeutically sufficient quantities.
high blood pressure), because it has now beenmedically
established that the sodium ion contributes to hyperten 65 Thus, a need exists for a Z-acetoxybenzoic acid deriva
tive, wherein transient blocking of the carboxylic func
sion. Thirdly, the alkaline nature of the product per se
tion occurs, yet wherein the blocking group is not so
alters the pH of the blood and urine. to the alkaline side.
Chronic use of this product could thus initiate alkalosis.
tenaciously bound thereto.

4,242,330
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SUMMARY OF THE INVENTION
Accordingly, it is one object of the present invention
to provide a derivative of Z-acetoxybenzoic acid which

4
-continued

(1])

GLACIAL ACETIC ACID

9 Ho

2N H2504 HEAT

does not tend to cause local irritation of the gastrointes- 5

0

tinal tract, yet which is capable of hydrolyzing at a rate
sufficient to release 2-acetoxybenzoic acid in vivo in

(HA)

therapeutically sufficient quantities.
ll

It is another object of the present invention to pro
vide a derivative of 2-acetoxybenzoic acid which will 10

c-c1

(TIA) +

permit a therapeutically effective compound to be ab
sorbed through the gastrointestinal lining, in a manner

PYRIDINE

o-c-cn; —"9

such that insoluble, acidic particles of 2-acetoxybenzoic

ll

0

acid are not contacted therewith, thus eliminating gas

trointestinal bleeding.

CHZOBZ

15

ll

Finally, it is yet another object of the present inven
tion, to provide a derivative of 2-acetoxybenz0ic acid,

c-o-rm

which can be formulated in a suitable oral pharmaceuti

cally acceptable dosage form for administration as an
analgesic, an antipyretic, an anti-in?ammatory and an
antirheumatic agent to warm-blooded animals.
These and other objects of the instant invention will
become more readily apparent from a reading of the

OH

(III) + “Fm/C

accompanying disclosure and appended claims thereto.
The foregoing objects are attained with the use of a 25

60—>.
PS1

ll

HO

(3-0
0

o-g-cn;

novel acylal derivative of 2-acetoxybenzoic acid, i.e.,

l-O-(2'-acetoxy)benzoyl-a-D-2-deoxyglucopyranose.

CHZOH

O

The structure of this compound may be represented as

PRODUCT

follows:
30

H

OH
_0

HO

O

35

CHzOl-I

The above method is basically a modi?cation of the
method reported by Glaudemans and Fletcher in Meth
ods of Carbohydrate Chemistry. Vol. VI, R. L. Whistler
and J. N. Bemiller, Eds., Academic Press, New York,
New York (1972), pp. 373—376.
Numerous modi?cations in the depicted reaction
scheme will be apparent to those skilled in the art. For
example, protecting groups other than benzyl can be
employed, so long as they can be readily removed after '

40 coupling of the a-D-Z-deoxyglucopyranose and 2

DETAILED DESCRIPTION OF THE
INVENTION

acetoxybenzoic acid portions of the molecule. Thus,

p-methoxybenzyl or tert-butyl radicals could be intro
duced into the glucopyranose molecule instead of the

l-O-(2’-acetoxy)benzoyl-a-D-Z-deoxyglucopyranose
can be synthesized according to the following scheme:

benzyl protecting groups. After coupling, benzyl and
45 p-methoxybenzyl protecting groups can be conve

niently removed by catalytic hydrogenolysis. Suitable
catalysts may include rhodium, platinum, ruthenium,

OH

HO

CI‘I3OH + HQ

HCl
HEAT

Raney nickel and palladium (optionally on a support), a

——>

particularly preferred catalyst being palladium-on-car

0

5O

radicals, are employed, removal may be effected by use

OH

CI-h-O

of an acid such as tri?uoroacetic acid.

Ho

55
O

(I)

CI'IZOH

CHZCI
(I) +

bon. When protecting groups which are normally not

sensitive to catalytic hydrogenolysis, e. g., tert-butyl

CHZOH

KOH

_—9
HEAT
B2 = —CH2¢

OBz

crn-o

B20

in the presence of suitable bases other than pyridine,
e.g., other tertiary aliphatic or aromatic amines such as

60 N-methylmorpholine, triethylamine, and picoline, con
veniently in a non-protic solvent. Alternatively, the
protected glucopyranose could be reacted with 2
acetoxybenzoic acid (rather than with the acid chlo
ride), in which case the reaction would be conducted in
65 the presence of a suitable dehydrating agent, for exam

ple, an aromatic or aliphatic carbodiimide.
The invention will appear more fully from the exam‘

O

(n)

Variations in the coupling reaction would also be

possible. For example, the acid chloride starting mate
rial could be reacted with the protected glucopyranose

CHZOBZ

ples which follow.

5
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Preparation , of l-O-methyl-a-D-Z-deoxyglucopyranose

twenty-four hours. Filtration and washing with two
sixty-milliliter portions of .methanol resulted in 14 grams
(65% yield) of a white powder. Melting point: 96°—97°

Fifteen grams (0.09 moles) of 2-deoxyglucose were
dissolved in 540 milliliters of 2% methanolic hydrochlo

s,l,1—H), 64.2—5.l(m,6,4>-CI;I2—O—), 83.2-4.2(m,6,3

' EXAMPLE 1

C. NMR (CDCl3): 86.7—7.7(m,15,ArI;I), 85.1-54 (broad

through 6-glucose-H's and l-OH), 61.4—2.5(m,2,2-posi
tion).

ric acid and the solution was warmed to 40° C. in a

water bath. The solution was shaken occasionally for
one hour, then allowed to cool to room temperature and

EXAMPLE 4

stirred with thirty-two grams of sodium carbonate for
?fteen minutes. The solution was ?ltered and the ?ltrate 10
was concentrated under diminished pressure to yield a

Preparation of

l-O-(2’-acetoxy)benzoyl-3,4,6-tri-O-benzyl-a-D-2
deoxyglucopyranose.

light yellow oil containing a small amount of white
solid. The oily mixture was then stirred vigorously with
750 milliliters of acetone for thirty minutes. The result

A solution of 13.7 grams (0.032 moles) of 3,4,6-tri-O
benzyl-a-D-2—deoxyglucopyranose in 130 milliliters of

ing suspension was ?ltered and the ?ltrate was concen
trated under diminished pressure to yield a clear light

dichloromethane was treated with a solution of 6.93

grams (0.035 moles ) o-acetylsalicyloyl chloride and 2.8
milliliters of dry pyridine in ?fty milliliters of dichloro

yellow oil. The oil was combined with ?ve milliliters of
absolute ethanol and the mixture stored at —20° C.

methane and the resulting mixture was stirred at room

Large clear crystals of l-O-methyl-a-D-Z-deoxy

glucopyranose separated spontaneously after two to 20 temperature. After twenty-three hours, 100 grams of ice
were added and stirring was continued for one hour.
three days. The crystalline material was recovered by
The bi-layered mixture was transferred to a separatory
?ltration and washed with cold (—20° C.) ethyl acetate.
funnel and, the dichloromethane layer was washed suc
NMR
(DMSO-d@):
84.1-4.8(m,3,—O—H),63
cessively with water, 3 N sulfuric acid, water, and a

.1-4.l(m,9,3—6 H's,l H, —OCI;I3), 81. l—2.3(m,2,2—H's).

25 saturated ‘aqueous solution of sodium bicarbonate. The

dichloromethane layer was then dried over anhydrous
sodium sulfate and ?ltered, and the ?ltrate was concen
trated under diminished pressure to a clear oil in nearly

EXAMPLE 2

Preparation of

l-O-methyl-3,4,6-tri-O-benzyl-a-D-2-deoxy
glucopyranose
Nine grams (0.05 moles) of l-O-methyl-ot-D-Z-deoxy

quantitative yield. The oil, however, was found to con
30 tain varying amounts of a second component. This ma

terial was removed by dissolving the oily product in 200

glucopyranose was added to a suspension of 44.8 grams

milliliters of methanol at room temperature and then

of ?nely powdered potassium hydroxide in 110 milli

cooling the resultant solution to —20° C. The desired
product was isolated as a waxy solid by decanting the
methanol layer. This procedure was repeated with 50
milliliters of methanol, when necessary, to produce a
unitary compound (TLC on silica gel with a mobile

liters of dry dioxane and the mixture was warmed to
re?ux. When the reaction mixture was re?uxing

smoothly, sixty-two milliliters of colorless benzyl chlo
ride was added dropwise over a period of about forty
?ve minutes. The mixture was re?uxed for an additional

period of three hours. The residue was cooled, diluted

phase of chloroform/heptane/methanol/formic acid at
50/ 50/ 5/ l, Rf:0.57). The product was then isolated, in
25% yield, as white, crystalline ?akes by recrystalliza
tion from absolute ethanol (twenty milliliters per gram

with water to a total volume of 350 milliliters, and ex

of product). NMR (CDC13): 66.7-8.0(m,l9,ArH),

period of forty minutes, then cooled. The apparatus was
rearranged and the dioxane was distilled off over a

tracted successively with 300, 200, 100 and 100 milliliter
portions of ether. The ether portions were combined

85.8(d, 1,1-H),
84.4-4.9(m,6,
—-CI;l2—O—),
83.4-3.9(m,5,3-through 6-position-H’s), 6l.0—2.5(m,5,2

and dried over anhydrous sodium sulfate, then were
?ltered. Ether was removed from the ?ltrate under

position and —OCOCI;I3).
EXAMPLE 5

diminished pressure to yield a light yellow oil. The oily
material was subjected to vacuum (10*4 mm Hg) distil

,

Preparation of

l-O-(2'-acetoxy)benzoyl—a-D-2-deoxyglucopyranose

lation with the bath temperature slowly increased to
200° C. The product, an amber-colored oil, remained in
the distillation pot in 96—l00% yield. NMR (CDC13);

One gram of l-O-(2’-acetoxy)benzoyl-3,4,6-tri-O-ben
gyl-a-D-Z-deoxyglucopyranose was dissolved in 150
milliliters of absolute ethanol in a Parr bottle and 0.6
grams of 10% Pd/C was added. Hydrogenolysis at 60
pounds per square inch of hydrogen pressure was car

86.7—7.7(m,l5,ArI;I), 64.2-5.0(m,7,¢-C}_I2—O—- and

l—H),
?3.4—4.2(m,5,3-through
6-glucose-H's),
83.2(s,3,——OCI;I3), 8l.4—2.5 (m,2,2-position-H's).
EXAMPLE 3

55 ried out for twelve hours. The reaction mixture was

Preparation of

then ?ltered and the ?ltrate was concentrated under
diminished pressure to a clear oil. The oil was washed

3,4,6-tri-O-benzyl-a-D-2-deoxyglucopyranose

with one ?fty-milliliter portion of petroleum ether. The
The amber oil obtained in Example 2 (22.3 grams,
product crystallized spontaneously in 95—l00% yields
0.05 moles) was dissolved in 550 milliliters of hot (70° 60 upon the addition of ?fteen milliliters of chloroform.

C.) glacial acetic acid, 240 milliliters of hot (70° C.)
molar sulfuric acid were slowly added, and the, resulting
mixture was maintained at 73°-75° C. for one hour.

(The sulfuric acid was added slowly and with vigorous
stirring to prevent precipitation of the starting mate 65

NMR(acetone-d6): 87.0—8.2(m,4,ArH), 85.8-5.9(d,1,l

H), 83.0-4.l(m8,3-through 6-H’s and —OH’s), 82.3(s,3,

—OCOCI;I3), 81.0-2.3(m2,2-H’s).
EXAMPLE 6

rial.) The reaction mixture was then slowly added to

At low pH, the absorbance spectrum of l-O-(2’

three liters of vigorously stirred water. The mixture was
stirred for two hours, then was kept at +10° C. for

acetoxy)benzoyl-a-D-2-deoxyglucopyranose exhibits a
large peak at 278 nanometers which is exactly like that

4,242,330
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8
l-O-(2’-acetoxy)benzoyl-a-D-glucopyranose

observed for the unionized aspirin molecule. At a pH

raphy.

value of 6, the spectrum of the prodrug of the present
invention remains unchanged, while that observed for
the (ionized) aspirin molecule exhibits a signi?cant de

was found to have a half-life of hydrolysis to aspirin of
55 hours.

crease in absorbance at wavelengths of 270 to 290 nano
meters. Therefore, the decrease in absorbance of a solu

ministered in oral dosage form, such as by tablet or
capsule, by combining the same in a therapeutic amount

The compound of this invention is conveniently ad

tion containing both the prodrug of this invention and
aspirin observed at 285 nanometers upon adjustment of

(e.g., dosage regimen for aspirin on an equivalent

weight basis) with any oral pharmaceutically accept

the pH to a value of six is proportional to the amount of

aspirin in the solution.

10

Accordingly, the rate of generation of aspirin via

able inert carrier, such as lactose, starch (pharmaceuti

cal grade), dicalcium phosphate, calcium sulfate, kaolin,
mannitol, and powdered sugar. In addition, when re

hydrolysis of the derivative of the present invention

quired, suitable binders, lubricants, disintegrating

was determined spectrophotometrically at 285 nm. So

agents, and coloring agents can also be added. Typical

lutions
of
l-O-(2’-acetoxy)benzoylaa-D-2-deoxy
glucopyranose in a buffered solution containing 5
mg/ml were freshly prepared and maintained at con
stant temperature in a circulating waterbath. An aliquot

binders include starch, gelatin, sugars, such as sucrose,

molasses, and lactose, natural and synthetic gums such
as acacia, sodium alginate, extract of Irish moss, carbox

ymethylcellulose, methylcellulose, and polyvinylpyr

of 200 pl of the solution was added to 3 ml of buffered
solution at pH 6 in a 1 cm path-length spectrophotome

rolidone, polyethyleneglycol, ethylcellulose and waxes.

ter cell (Cary cell), and, after inverting several times to

Typical lubricants for use in these dosage forms can

insure a uniform mixture, the absorbance versus a buff
er-only blank was observed at 285 nm. Buffers em

include, without limitation, sodium benzoate, sodium
acetate, sodium chloride, leucine and polyethyleneg
lycol. Suitable disintegrators can include, without limi

ployed were hydrochloric acid (pH 1 to 2), citrate (pl-I
3), acetate (pH 4 to 6) and phosphate (pH 7-9). Ionic
strength was adjusted with potassium chloride (usually

tation, starch, methylcellulose, agar, bentonite, cellu
lose and wood products, alginic acid, guar gum, citrus

to 0.1). The change in absorbance at 285 nm was fol
lowed until no change in absorbance was observed.

pulp, carboxymethylcellulose and sodium lauryl sulfate.
If desired, a conventionally pharmaceutically accept

First order plots were constructed by plotting log

able dye can be incorporated into the dosage unit form,

(Ar-Aw) agains time. The effect of pH on the rate of

hydrolysis was determined using solutions ranging from

pH 1.2 to pH 9.
The generation of aspirin from the derivative was
found to be independent of the pH of the solutions as
shown in the Table. The half-life for the hydrolysis at
pH 3 and pH 8 at 37° C. was found to be 7 minutes.
TABLE

i.e., any of the standard FD&C dyes.
30

PHARMACEUTICAL SCIENCE ,” Fourteenth Edi

tion (1970), pp. 1659-1698, inclusive.
35

THE HALF-LIFE OF HYDROLYSIS OF l-O-(2"
TO ASPIRIN AS A FUNCTION OF pH AT 37" C.

tl/2‘(minutes)

3
4.6
6.4
s
9

7
7.1
7.0
1.02
1.0

The dose administered, whether a single dose or a

daily dose will, of course, vary with the needs of the
individual being treated. However, the dosage adminis
tered is not subject to de?nite bounds, but it will usually

ACETOXY)BENZOYL-a-D-Z-DEOXYGLUCOPYRANOSE
pH

Any skilled artisan can prepare these oral dosage

forms by simply referring to the oral dosage form pre
paratory procedure outlined in “REMINGTON’S

be an effective therapeutic amount, or the equivalent on
a molar basis of the pharmacologically-active form

produced upon the metabolic release of the active drug
(2-acetoxybenzoic acid) to achieve its desired pharma
cological or physiological effect.
Although the present invention has been adequately
‘Each half-life is the average of three determinations.
45 described in the foregoing speci?cation and examples
included therein, it is apparent that various changes
Thus, the transient blocking of the acidic carboxylic
and/or modi?cations can be made thereto by the skilled
group of aspirin by formation of an acylal-linked deriva
artisan
without departing from the spirit and scope
tive results in a compound which regenerates aspirin at

an acceptable rate. Such a compound reduces the gas 50 thereof. Such changes and/or modi?cations are prop

erly, equitably and intended to be within the full range

trointestinal liability of aspirin by presenting a neutral

of equivalence of the following claims.

molecule to the gastric membrane.

What is claimed is:

EXAMPLE 7

1. The compound l-O-(2’-acetoxy)benzoyl-a-D-2

deoxyglucopyranose.

The rate of hydrolysis of l-O-(2'-acetoxy)benzoyl-a

2. A method for inducing an analgesic, antipyretic,

D-glucopyranose, i.e., the compound of the formula

antirheumatic or anti-in?ammatory response in a warm

blooded animal which comprises orally administering

on

thereto an effective amount of l-O-(2'-acetoxy)benzoyl

3

OH

c_o

a-D-2-deoxyglucopyranose.

no

3. A pharmaceutical composition of matter adapted
for oral administration comprising an effective analge

0

sic, antipyretic, antirheumatic or anti-in?ammatory
CHZOI-I

was determined by following the rate of appearance of

amount of l-O-(2’-acetoxy)benzoyl-a-D-2-deoxy
glucopyranose and a pharmaceutically acceptable inert
carrier.
4. The method as de?ned by claim 2, for inducing an

aspirin in a solution by high pressure liquid chromatog

analgesic response.

65

4,242,330

9

10 _

s. The method as de?ned by claim 2, for inducing an

11- The °°mP°Slll°" of 91mm 3, comp?smg a" mil-"r

?ammatory amount of said glucopyranose.
12. A compound having the structural formula:

annpyrenc response‘
6. The method as defined by claim 2, for inducing an
antirheumatic response.

5

7. The method as de?ned by claim 2, for inducing an
anti-in?ammatory response.

E_o

8. The composition of claim 3, comprising an analge-

sic amount of said glucopyranose.

.

‘

‘0

R0

OR

o

O-?"CH3 CHZOR

9. The composition of claim 3, comprising an antipy- "
retic amount of said glucopyranose.
wherein R is selected from the group consisting of ben
10. The composition of claim 3, comprising an anti
zyl, p-methoxybenzyl and tert-butyl.
a
o
u
a
a
rheumatic amount of said glucopyranose.
15
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